Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 5 of 5 results for decitabine

  1. Decitabine for untreated acute myeloid leukaemia (terminated appraisal) (TA548)

    NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia. This is because Janssen did not provide an evidence submission.

    Technology appraisal guidance
    Published
    5 December 2018

    Sections for TA548

  2. Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) (TA270)

    NICE is unable to recommend the use in the NHS of decitabine for acute myeloid leukaemia. This is because Janssen did not provide an evidence submission.

    Technology appraisal guidance
    Published
    12 December 2012

    Sections for TA270

  3. Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) (TA932)

    NICE is unable to make a recommendation on decitabine–cedazuridine (Inaqovi) for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable. This is because Otsuka Pharmaceuticals (UK) did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    23 November 2023

    Sections for TA932

  4. Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]

    In development Reference number: GID-TA11765 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 11 February 2026.

    Technology appraisal guidance
    In consultation